Developer docs
API playgroundTry for free, no card

Search company profiles

Orphalan

Full company profile

uuid0007mko

Namestring
Orphalan
Legal namestring
Orphalan SA
Websiteurl
orphalan.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Orphalan SA is a privately held French pharmaceutical company founded in 2011 and headquartered in Paris that develops and commercializes treatments for rare diseases, anchored by a franchise in Wilson's disease — a rare genetic disorder of copper metabolism. The company's core technology is a proprietary trientine tetrahydrochloride (TETA-4HCl) formulation marketed under the brand names Cuprior (EU, UK, Saudi Arabia, Switzerland, Colombia, New Zealand), Cuvrior (United States, approved by the FDA in May 2022), and Ke Pei Ou (China, NMPA-approved January 2024). The FDA approval marked the first new Wilson's disease treatment authorized in the United States in over five decades and was supported by the CHELATE Phase 3 trial, the first prospective randomized comparison of trientine tetrahydrochloride versus d-penicillamine, published in The Lancet Gastroenterology & Hepatology. Orphalan has also developed a proprietary Non-Ceruloplasmin Copper (NCC) assay in consultation with the FDA for more accurate disease monitoring, and operates the International Wilson's Disease Patient Registry (iWD Registry) as a real-world evidence platform.

The company generates revenue through direct prescription pharmaceutical product sales in markets where it operates its own commercial organization (Europe, United States) and through distribution partnerships elsewhere, notably the SPH Kyuan Trade (Shanghai Pharma Group) partnership for China. Its customer base is concentrated in specialist prescribers — hepatologists, neurologists, and pediatric specialists — treating a narrow, orphan-indication patient pool across more than 30 countries, with over 1,800 patients treated cumulatively. Following the December 2025 acquisition of Orphelia Pharma, Orphalan expanded into rare and serious pediatric diseases in neurology and oncology, including KIZFIZO, a first liquid oral formulation of temozolomide for relapsed or refractory neuroblastoma developed with Gustave Roussy. With 100+ employees, dedicated teams in 20+ countries, and a hybrid direct-sales and partner-distribution go-to-market model, Orphalan functions as a vertically integrated rare disease commercial platform rather than a single-asset biotech.

Short descriptiontext

Orphalan SA is a privately held Paris-based pharmaceutical company that develops and commercializes orphan drug treatments for rare diseases, anchored by trientine tetrahydrochloride products for Wilson's disease sold in 30+ countries and an expanding pediatric rare disease franchise acquired from Orphelia Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices11 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug development, rare disease therapeutics, Wilson's disease treatment, pharmaceutical commercialization, specialty orphan drugs
Industry3 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Orphan Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of trientine tetrahydrochloride products (Cuprior, Cuvrior, Ke Pei Ou) for Wilson's disease treatment. Products are available in 30+ countries under various brand names.

orphalan.com
2Drug Development and Commercialization
TypeLicensing Royalties
Description

Orphalan identifies, develops and delivers innovative treatments for rare diseases. The company commercializes its own products through direct sales teams and distribution partnerships.

orphalan.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Cuprior
Description

Trientine tetrahydrochloride product marketed in EU, UK, Saudi Arabia, Switzerland, Colombia, and New Zealand for Wilson's Disease treatment

orphalan.com
+2 more records
Core offering1 text field

Orphalan identifies, develops, and commercializes orphan drug treatments for rare diseases, with a primary focus on Wilson's disease. Its lead product is a trientine tetrahydrochloride (TETA-4HCl) formulation marketed under multiple brand names (Cuprior, Cuvrior, Ke Pei Ou) across 30+ countries. The company also develops pediatric rare-disease treatments such as KIZFIZO, a liquid oral formulation of temozolomide for relapsed or refractory neuroblastoma in children.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 50% of patients treated with trientine tetrahydrochloride achieved pre-specified composite endpoint vs 24% with d-penicillamine
+2 more records
Product and service4 records
1Cuprior
CategoryOrphan Pharmaceutical
Description

Oral trientine tetrahydrochloride formulation approved for Wilson's disease maintenance therapy in adults and children aged 5 years and older who are intolerant to penicillamine; marketed in Europe, UK, Saudi Arabia, Switzerland, Colombia, and New Zealand.

2Cuvrior
CategoryOrphan Pharmaceutical
Description

Trientine tetrahydrochloride (TETA-4HCl) approved by the FDA for adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine; the first FDA-approved Wilson's disease therapy in over 50 years.

3Ke Pei Ou (科佩欧®)
CategoryOrphan Pharmaceutical
Description

Trientine tetrahydrochloride product marketed in China for Wilson's disease treatment in children aged five years and older and adults intolerant to penicillamine therapy.

4KIZFIZO
CategoryPediatric Oncology Orphan Pharmaceutical
Description

Liquid oral formulation of temozolomide developed in collaboration with Gustave Roussy for treating relapsed or refractory neuroblastoma in children; first liquid oral formulation of temozolomide with orphan drug designations in Europe and the US.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-12
Description

Orphalan acquired Orphelia Pharma, a French pharmaceutical company dedicated to rare and serious pediatric diseases in neurology and oncology. This acquisition expands Orphalan's therapeutic portfolio and strengthens its position as a European leader in rare diseases.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-06-27
Description

Partnership with MAP International to provide Cuvrior (trientine tetrahydrochloride) to underserved communities globally. MAP International is a Christian health organization committed to providing essential medicines to those in need.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-06-27
Description

Partnership with Wilson Disease Association to provide Cuvrior to underserved communities. WDA is a patient advocacy organization supporting individuals and families affected by Wilson's disease.

4SPH Kyuan Trade (Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-07
Description

Strategic partnership with SPH Kyuan Trade, a leading pharmaceutical distributor in China and subsidiary of Shanghai Pharma Group, one of China's largest healthcare conglomerates. Partnership to transform access to Wilson's disease treatment for Chinese patients.

orphalan.com
5International Wilson's Disease Patient Registry (iWD Registry) Partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-26
Description

Orphalan established the first global Wilson's Disease Patient Registry in collaboration with international physicians and research institutions. Initial enrollment sites include Children's Memorial Health Institute (Warsaw) and Institute of Psychiatry and Neurology (Warsaw), with plans to expand to Belgium, Spain, Germany, UK, and France.

orphalan.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Gustave Roussy for development of KIZFIZO, the first liquid oral formulation of temozolomide for treating relapsed or refractory neuroblastoma in children. Gustave Roussy is a leading cancer research center.

7Wuhan Tongxin (Wilson Disease Patient Group in China)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Wilson disease patient group in China that expressed support for NMPA approval of Orphalan's trientine tetrahydrochloride product.

orphalan.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Swiss privately-held specialty pharma focused on oncology and rare diseases with global commercial partnerships. Comparable as a mid-sized European orphan-drug developer/commercializer with selective geographic expansion.

TypeBroad incumbent
Description

US rare-disease specialist focused on genetic and metabolic disorders with global commercialization. Comparable in targeting small, genetically-defined patient populations with premium-priced orphan therapies.

TypeDirect peer
Description

Recordati's rare disease arm markets Wilzin (zinc acetate), a competing first-line Wilson's disease maintenance therapy. Most direct competitor in Orphalan's core indication, targeting the same prescribers and patient populations.

TypeBroad incumbent
Description

European-headquartered rare-disease specialist with a portfolio spanning hematology, immunology, and specialty metabolic disorders. Highly comparable in size, geographic footprint, and rare-disease commercial approach.

TypeBroad incumbent
Description

Specialty pharma focused on rare neurological and oncology indications with global commercial reach. Comparable in targeting small specialist prescriber bases with high-value orphan therapies.

TypeBroad incumbent
Description

Pioneer in rare-disease commercialization (Cerezyme, Fabrazyme, Myozyme). Several Genzyme-trained executives now lead Orphalan, and the operational model — direct rare-disease sales infrastructure globally — closely mirrors Orphalan's.

TypeBroad incumbent
Description

Commercial-stage rare-disease company with strong global infrastructure in genetic diseases (cystic fibrosis, sickle cell). Comparable in leveraging orphan drug exclusivity and global rollout of specialty therapeutics.

TypeBroad incumbent
Description

Global rare-disease leader (Soliris, Strensiq, Kanuma) operating with a similar specialty pharma commercial model targeting rare metabolic and neurological disorders. Comparable in go-to-market approach for ultra-rare conditions.

TypeEmerging player
Description

French pediatric rare-disease company now wholly owned by Orphalan (acquired December 2025). Directly comparable as the developer of KIZFIZO and a peer-now-subsidiary in pediatric orphan therapeutics.

TypeEmerging player
Description

Clinical-to-commercial rare-disease company focused on genetic and metabolic disorders. Comparable in pursuing orphan drug approvals across multiple jurisdictions for ultra-rare conditions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orphalan

Orphan Pharmaceuticalsorphalan.com

Orphalan SA is a privately held Paris-based pharmaceutical company that develops and commercializes orphan drug treatments for rare diseases, anchored by trientine tetrahydrochloride products for Wilson's disease sold in 30+ countries and an expanding pediatric rare disease franchise acquired from Orphelia Pharma.

What Orphalan does

Orphalan SA is a privately held French pharmaceutical company founded in 2011 and headquartered in Paris that develops and commercializes treatments for rare diseases, anchored by a franchise in Wilson's disease — a rare genetic disorder of copper metabolism. The company's core technology is a proprietary trientine tetrahydrochloride (TETA-4HCl) formulation marketed under the brand names Cuprior (EU, UK, Saudi Arabia, Switzerland, Colombia, New Zealand), Cuvrior (United States, approved by the FDA in May 2022), and Ke Pei Ou (China, NMPA-approved January 2024). The FDA approval marked the first new Wilson's disease treatment authorized in the United States in over five decades and was supported by the CHELATE Phase 3 trial, the first prospective randomized comparison of trientine tetrahydrochloride versus d-penicillamine, published in The Lancet Gastroenterology & Hepatology. Orphalan has also developed a proprietary Non-Ceruloplasmin Copper (NCC) assay in consultation with the FDA for more accurate disease monitoring, and operates the International Wilson's Disease Patient Registry (iWD Registry) as a real-world evidence platform.

The company generates revenue through direct prescription pharmaceutical product sales in markets where it operates its own commercial organization (Europe, United States) and through distribution partnerships elsewhere, notably the SPH Kyuan Trade (Shanghai Pharma Group) partnership for China. Its customer base is concentrated in specialist prescribers — hepatologists, neurologists, and pediatric specialists — treating a narrow, orphan-indication patient pool across more than 30 countries, with over 1,800 patients treated cumulatively. Following the December 2025 acquisition of Orphelia Pharma, Orphalan expanded into rare and serious pediatric diseases in neurology and oncology, including KIZFIZO, a first liquid oral formulation of temozolomide for relapsed or refractory neuroblastoma developed with Gustave Roussy. With 100+ employees, dedicated teams in 20+ countries, and a hybrid direct-sales and partner-distribution go-to-market model, Orphalan functions as a vertically integrated rare disease commercial platform rather than a single-asset biotech.

Orphalan firmographics

Firmographics
Name
Orphalan
Legal name
Orphalan SA
Website
https://orphalan.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Orphalan SA is a privately held Paris-based pharmaceutical company that develops and commercializes orphan drug treatments for rare diseases, anchored by trientine tetrahydrochloride products for Wilson's disease sold in 30+ countries and an expanding pediatric rare disease franchise acquired from Orphelia Pharma.
Ownership category
akta.pro rank

Orphalan industry classification

Industry
Product category
Orphan Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug development
  • Rare disease therapeutics
  • Wilson's disease treatment
  • Pharmaceutical commercialization
  • Specialty orphan drugs

Where Orphalan is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices11 records

Markets served

Orphalan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of trientine tetrahydrochloride products (Cuprior, Cuvrior, Ke Pei Ou) for Wilson's disease treatment. Products are available in 30+ countries under various brand names.
  2. Drug Development and Commercialization: Orphalan identifies, develops and delivers innovative treatments for rare diseases. The company commercializes its own products through direct sales teams and distribution partnerships.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Orphalan product offering

Product offering

Core offering

Orphalan identifies, develops, and commercializes orphan drug treatments for rare diseases, with a primary focus on Wilson's disease. Its lead product is a trientine tetrahydrochloride (TETA-4HCl) formulation marketed under multiple brand names (Cuprior, Cuvrior, Ke Pei Ou) across 30+ countries. The company also develops pediatric rare-disease treatments such as KIZFIZO, a liquid oral formulation of temozolomide for relapsed or refractory neuroblastoma in children.

Differentiator

Problem solved

Functional benefit

Brands

  • Cuprior: Trientine tetrahydrochloride product marketed in EU, UK, Saudi Arabia, Switzerland, Colombia, and New Zealand for Wilson's Disease treatment
  • Cuvrior
  • Ke Pei Ou (科佩欧)

Products and services

  • Cuprior Oral trientine tetrahydrochloride formulation approved for Wilson's disease maintenance therapy in adults and children aged 5 years and older who are intolerant to penicillamine; marketed in Europe, UK, Saudi Arabia, Switzerland, Colombia, and New Zealand.
  • Cuvrior Trientine tetrahydrochloride (TETA-4HCl) approved by the FDA for adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine; the first FDA-approved Wilson's disease therapy in over 50 years.
  • Ke Pei Ou (科佩欧®) Trientine tetrahydrochloride product marketed in China for Wilson's disease treatment in children aged five years and older and adults intolerant to penicillamine therapy.
  • KIZFIZO Liquid oral formulation of temozolomide developed in collaboration with Gustave Roussy for treating relapsed or refractory neuroblastoma in children; first liquid oral formulation of temozolomide with orphan drug designations in Europe and the US.

Quantifiable outcome

  • 50% of patients treated with trientine tetrahydrochloride achieved pre-specified composite endpoint vs 24% with d-penicillamine
  • +2 more outcomes

Companies that use Orphalan

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Orphalan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Orphalan partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Orphelia PharmacoreStrategic or Co-development Partner · 12 December 2025Orphalan acquired Orphelia Pharma, a French pharmaceutical company dedicated to rare and serious pediatric diseases in neurology and oncology. This acquisition expands Orphalan's therapeutic portfolio and strengthens its position as a European leader in rare diseases.
  • MAP InternationalminorGTM or Marketing Partner · 27 June 2025Partnership with MAP International to provide Cuvrior (trientine tetrahydrochloride) to underserved communities globally. MAP International is a Christian health organization committed to providing essential medicines to those in need.
  • Wilson Disease Association (WDA)minorGTM or Marketing Partner · 27 June 2025Partnership with Wilson Disease Association to provide Cuvrior to underserved communities. WDA is a patient advocacy organization supporting individuals and families affected by Wilson's disease.
  • SPH Kyuan Trade (Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd)coreChannel Partner/ Reseller/ Distributor · 7 March 2025Strategic partnership with SPH Kyuan Trade, a leading pharmaceutical distributor in China and subsidiary of Shanghai Pharma Group, one of China's largest healthcare conglomerates. Partnership to transform access to Wilson's disease treatment for Chinese patients.
  • International Wilson's Disease Patient Registry (iWD Registry) PartnerscoreStrategic or Co-development Partner · 26 July 2022Orphalan established the first global Wilson's Disease Patient Registry in collaboration with international physicians and research institutions. Initial enrollment sites include Children's Memorial Health Institute (Warsaw) and Institute of Psychiatry and Neurology (Warsaw), with plans to expand to Belgium, Spain, Germany, UK, and France.
  • Gustave RoussycoreStrategic or Co-development PartnerCollaboration with Gustave Roussy for development of KIZFIZO, the first liquid oral formulation of temozolomide for treating relapsed or refractory neuroblastoma in children. Gustave Roussy is a leading cancer research center.
  • Wuhan Tongxin (Wilson Disease Patient Group in China)minorGTM or Marketing PartnerWilson disease patient group in China that expressed support for NMPA approval of Orphalan's trientine tetrahydrochloride product.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Orphalan competitors and assessment

Company assessment

Emerging players

  • Helsinn Group: Swiss privately-held specialty pharma focused on oncology and rare diseases with global commercial partnerships. Comparable as a mid-sized European orphan-drug developer/commercializer with selective geographic expansion.
  • Orphelia Pharma: French pediatric rare-disease company now wholly owned by Orphalan (acquired December 2025). Directly comparable as the developer of KIZFIZO and a peer-now-subsidiary in pediatric orphan therapeutics.
  • Ultragenyx Pharmaceutical: Clinical-to-commercial rare-disease company focused on genetic and metabolic disorders. Comparable in pursuing orphan drug approvals across multiple jurisdictions for ultra-rare conditions.

Broad incumbents

  • BioMarin Pharmaceutical: US rare-disease specialist focused on genetic and metabolic disorders with global commercialization. Comparable in targeting small, genetically-defined patient populations with premium-priced orphan therapies.
  • Swedish Orphan Biovitrum (Sobi): European-headquartered rare-disease specialist with a portfolio spanning hematology, immunology, and specialty metabolic disorders. Highly comparable in size, geographic footprint, and rare-disease commercial approach.
  • Jazz Pharmaceuticals: Specialty pharma focused on rare neurological and oncology indications with global commercial reach. Comparable in targeting small specialist prescriber bases with high-value orphan therapies.
  • Genzyme (Sanofi): Pioneer in rare-disease commercialization (Cerezyme, Fabrazyme, Myozyme). Several Genzyme-trained executives now lead Orphalan, and the operational model — direct rare-disease sales infrastructure globally — closely mirrors Orphalan's.
  • Vertex Pharmaceuticals: Commercial-stage rare-disease company with strong global infrastructure in genetic diseases (cystic fibrosis, sickle cell). Comparable in leveraging orphan drug exclusivity and global rollout of specialty therapeutics.
  • Alexion (AstraZeneca Rare Disease): Global rare-disease leader (Soliris, Strensiq, Kanuma) operating with a similar specialty pharma commercial model targeting rare metabolic and neurological disorders. Comparable in go-to-market approach for ultra-rare conditions.

Direct peers

  • Recordati Rare Diseases: Recordati's rare disease arm markets Wilzin (zinc acetate), a competing first-line Wilson's disease maintenance therapy. Most direct competitor in Orphalan's core indication, targeting the same prescribers and patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Orphalan social profiles

Digital presence

Orphalan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orphalan leadership team

Management profile

Number of profiles

Profiles6 records

Orphalan subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Orphalan funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orphalan M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orphalan

What does Orphalan do?

Orphalan identifies, develops, and commercializes orphan drug treatments for rare diseases, with a primary focus on Wilson's disease. Its lead product is a trientine tetrahydrochloride (TETA-4HCl) formulation marketed under multiple brand names (Cuprior, Cuvrior, Ke Pei Ou) across 30+ countries. The company also develops pediatric rare-disease treatments such as KIZFIZO, a liquid oral formulation of temozolomide for relapsed or refractory neuroblastoma in children.

Is Orphalan a public or private company?

Orphalan is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Orphalan founded?

Orphalan was founded in 2011. It employs 101 to 250 people.

Where is Orphalan based?

Orphalan is headquartered in Paris, France, in the Europe region.

How does Orphalan make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are drug Development and Commercialization.

Who are Orphalan's main competitors?

Emerging players on record are Helsinn Group, Orphelia Pharma and Ultragenyx Pharmaceutical. Broad incumbents are BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, Genzyme (Sanofi), Vertex Pharmaceuticals and Alexion (AstraZeneca Rare Disease). Recordati Rare Diseases is listed as a direct peer.

Does Orphalan have an API?

No public API is recorded for Orphalan.

What industry is Orphalan in?

Orphalan's product category is Orphan Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 3254 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOrphalan Expands Global Phase 3 TRADITiONAL Study in Wilson Disease to China Marking First Patient Randomised WorldwideOrphalan expanded its Phase 3 TRADITiONAL study into China, randomising the first participant at Zhejiang University Hospital. The trial compares once-daily trientine tetrahydrochloride to D-penicillamine for Wilson disease over 48 weeks. Recruitment is open at three Chinese sites, with additional sites expected in Pakistan.Clinical Trials ArenaOrphalan launches Phase III TRADITiONAL trial for Wilson diseaseOrphalan launched the TRADITiONAL Phase III trial of a once-daily trientine formulation for Wilson disease, comparing it to D-penicillamine. The 48-week study recruits symptomatic and asymptomatic patients aged eight and above, with initial US sites and expansion to Saudi Arabia, China, and Pakistan.PR NewswireOrphalan Initiates Global Phase 3 TRADITiONAL Study of Investigational Once-Daily Trientine Therapy in Wilson DiseaseOrphalan launched the TRADITiONAL Phase 3 study evaluating a once-daily trientine formulation versus D-penicillamine as first-line treatment for Wilson disease. The 48-week trial will assess safety, efficacy, and patient satisfaction in treatment-naïve or chelator-naïve patients. Global enrollment is expanding to China, Pakistan, and Saudi Arabia.PR NewswireOrphalan announces acquisition of Orphelia PharmaOrphalan, an international pharmaceutical company, acquired Orphelia Pharma, a firm specializing in rare pediatric diseases, on December 12, 2025. The acquisition aims to strengthen Orphalan's position in rare diseases and expand access to treatments globally.BioSpaceOrphalan announces acquisition of Orphelia PharmaOrphalan, an international pharmaceutical company specializing in orphan drugs, has acquired Orphelia Pharma, a Paris and Lyon-based company focused on rare and severe pediatric diseases in neurology and oncology. The strategic transaction expands Orphalan's therapeutic portfolio and strengthens its position as a European leader in rare diseases with global commercial capabilities. Orphelia Pharma brings one authorized medicine (Kigabeq®) in the European Union and a second product (Kizfizo®) currently under regulatory review.PR NewswireOrphalan announces acquisition of Orphelia PharmaOrphalan has acquired Orphelia Pharma, a pharmaceutical company focused on rare and severe pediatric diseases in neurology and oncology. The strategic transaction expands Orphalan's therapeutic portfolio and strengthens its position as a European leader with global commercialization capabilities in orphan drugs. The combined entity aims to accelerate innovation and improve patient access to treatments for rare conditions.GlobeNewswireOrphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved CommunitiesOrphalan SA is partnering with MAP International and the Wilson Disease Association to donate Cuvrior (trientine tetrahydrochloride) to patients with Wilson Disease in developing countries. The oral copper chelator, FDA-approved in 2022, is room-temperature stable and will be distributed via MAP International's network. Supplies are now available for shipment to patients in need globally.PR NewswireOrphalan becomes the first European company to enter in China's Wilson Disease marketOrphalan launched its Wilson's disease treatment Ke Pei Ou in China through a partnership with SPH Kyuan Trade, becoming the first European company to enter the Chinese Wilson Disease market. The trientine-based drug, already available in over 20 countries, is the first trientine treatment approved by China's NMPA. Orphalan also established a Shanghai entity to support the launch.GlobeNewswireOrphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson diseaseOrphalan announced that China's NMPA approved its trientine tetrahydrochloride product for Wilson disease, the first trientine approved in China. The product targets children aged five and older and adults intolerant to penicillamine, with an estimated 80,000 patients in China. Availability in the country is expected in coming months.